What does hFGF stand for?

Human Fibroblast Growth Factor

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Home Fellowship Group (various locations) Home Friendship Groups (Christian-based small group ministry) Honest Food Guide Human Factors Group Health Foundation of Greater Cincinnati (Ohio) Helen F Graham Cancer Center (Newark, DE) Humanist Friendship Group of Central Indiana High Frequency Global Communication System Hemophilia Foundation of Greater Florida Home for Good Foundation (Grants Pass, OR)		Human Fibroblast Growth Factor Receptor 3 Hope for Grace Kodindo (UK women health care helping Chad) Have Fun Good Luck Her Famed Good Looks High-Fidelity Generalized Method of Cells Hastings Fiber Glass Products (Hastings, MI) High-Frequency Gravitational Waves (astrophysics) Habitat For Humanity Hamburger Fern-Hochschule (German university senate) Heart Failure Hospitalization

Samples in periodicals archive:

These two devices will be used in CVBT's Phase II heart trial, in which the potent angiogenic protein human Fibroblast Growth Factor -1 (FGF-1) will be injected into patients' hearts.

CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II ...

Envisioned as a procedure that could be administered by interventional cardiologists, Ad5FGF-4 involves a one-time administration of an adenoviral gene therapy vector containing the human Fibroblast Growth Factor 4 (FGF4) angiogenic gene delivered into the coronary arteries through a standard catheter.

POSITIVE DATA ON SCHERING'S AD5FGF-4 FOR CHRONIC STABLE ANGINA

Recently, CardioVascular announced the completion of its Phase I wound healing FDA clinical trial evaluating the safety and tolerability of its protein-based drug candidate CVBT-141B for dermal wound healing, formulated with human fibroblast growth factor -1 (FGF-1).

Dutton Associates Announces Investment Opinion: CardioVascular ...

OTCBB: CVBT) today announced the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company's protein-based drug candidate (CVBT-141B), formulated with human fibroblast growth factor -1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers.

CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial

CVBT is developing a protein-based technology by which a member of the human Fibroblast Growth Factor family, known as Fibroblast Growth Factor-1 (FGF-1), stimulates angiogenesis, or new blood vessel growth.

CardioVascular BioTherapeutics to Present at Euro-Biotech Forum

Stegmann's landmark studies in which no-option heart patients received injections of human fibroblast growth factor established what he had suspected, "that we could grow new blood vessels that could re-direct blood flow around occluded arteries in the heart.

Dr. Thomas Stegmann, Cardiovascular Surgeon and Pioneer in Field of ...